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ABSTRACT 
Cytochrome P4507B1 7α-hydroxylates dehydroepiandrosterone (DHEA), 
epiandrosterone (EpiA) and 5α-androstane-3β,17β-diol (Adiol). 11β-Hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) interconverts 7α- and 7β- forms. Whether the inter-
conversion proceeds through oxido-reductive steps or epimerase activity is investigated. 
Experiments using 3H-labeled 7β-hydroxy-DHEA, 7β-hydroxy-EpiA and 7β-hydroxy-
Adiol show the 3H-label to accumulate in 7-oxo-DHEA trap but neither in 7-oxo-EpiA 
nor 7-oxo-Adiol traps. Computed models of 7-oxygenated steroids dock in the active site 
of 11β-HSD1 either in a flipped or turned form relative to cortisone and cortisol. 7-Oxo-
steroid reduction in 7α- or 7β-hydroxylated derivatives results from either turned or 
flipped forms. 11β-HSD1 incubation in H218O medium with each 7-hydroxysteroid did 
not incorporate 18O in 7-hydroxylated derivatives of EpiA and Adiol independently of 
the cofactor used. Thus oxido-reductive steps apply for the interconversion of 7α- and 
7β-hydroxy-DHEA through 7-oxo-DHEA. Epimerisation may proceed on the 7-
hydroxylated derivatives of EpiA and Adiol through a mechanism involving the cofactor 
and Ser170. 
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INTRODUCTION 
The 7α-hydroxylation of circulating dehydroepiandrosterone (DHEA), epiandrosterone 
(EpiA) and 5α-androstane-3β,17β-diol (Adiol) is catalyzed in animals and humans by the 
cytochrome P450 7B1 (CYP7B1)1,2,3. Thus, the 7α-hydroxylated derivatives of these steroids 
are found in human blood and urines4,5. Circulating 7α-hydroxy-DHEA is accompanied by 
almost equivalent quantities of 7β-hydroxy-DHEA6,7. Origin of 7β-hydroxy-DHEA and 7β-
hydroxy-EpiA was investigated in several human models8,9. Use of a yeast-expressed 
recombinant human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) helped to 
demonstrate that 7β-hydroxy-DHEA derived from 7α-hydroxy-DHEA through a 7-oxo-
DHEA intermediate10,11 (Fig. 1). Thus, the human 11β-HSD1 catalyzed the interconversion of 
7α- and 7β-hydroxy-DHEA through its oxido-reductive activity on 7-hydroxylated DHEA 
substrates. Whether this occurred with the 7-hydroxylated derivatives of EpiA and Adiol was 
also investigated. Indeed inter-conversion of the 7α- and 7β-hydroxysteroids was obtained by 
use of human tissue preparations8,9 and recombinant human 11β-HSD112,13. Nevertheless, no 
production of a putative 7-oxo intermediate could be detected and it was hypothesized that the 
human 11β-HSD1 would act as an epimerase on the 7α- and 7β-hydroxylated derivatives of 
EpiA and Adiol. In contrast, when either 7-oxo-EpiA12 or 7-oxo-Adiol13 were used as 
substrates for the 11β-HSD1 in the presence of NADPH, reduction into 7α- and 7β-hydroxy 
derivatives was obtained (Fig. 1). 
In this work, our aims were to assess the 11β-HSD1-mediated interconversion of 7α-
hydroxy-EpiA and 7α-hydroxy-Adiol into their respective 7β-hydroxylated derivatives, and 
to ascertain whether traces of 7-oxo intermediaries were produced. To these ends, we used the 
recombinant human 11β-HSD1 and radio-labelled steroid substrates through experiments 
where the non radioactive 7-oxo-steroids were used as traps for their putative production by 
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the enzyme. In order to asses the mechanism taking place at the 11β-HSD1 active site, models 
of each 7-oxygenated steroid were computed and docked in the available crystal structure of 
human 11β-HSD1. This led to mechanistic assessment of the epimerisation mechanism. 
 
RESULTS 
Incubation of [3H]-7β-hydroxy-DHEA, 7β-hydroxy-EpiA and 7β-hydroxy-Adiol in 
presence of respective 7-oxo-steroid traps 
Absence of the enzyme or use of a boiled preparation resulted in no metabolism. No 11β-
HSD1-mediated conversion of the substrates was found when cofactor was absent. NADP+ 
supplementation led to the recovery of 38.8% of the radioactive label in the 7-oxo-DHEA 
fraction (Table 1). This proves that our experimental approach assesses the NADP+-
dependent oxidation of 7β-hydroxy-DHEA to 7-oxo-DHEA catalyzed by the recombinant 
human 11β-HSD1, and that NADPH is not generated in sufficient quantities from NADP+ for 
catalysis of 7α-hydroxy-DHEA production. In contrast, no radioactivity deriving from the 
[3H]-5α-reduced substrates was detected in 7-oxo-EpiA and 7-oxo-Adiol traps (Table 1). In 
[3H]-7β-hydroxy-EpiA incubations, a portion of the radioactive label was recovered in the 
7α-hydroxy-EpiA fraction after NADPH (1.3%) and NADP+ (1.0%) supplementation. In 
[3H]-7β-hydroxy-Adiol incubations, a portion of the radioactive label was recovered in the 
7α-hydroxy-Adiol fraction after NADPH (7.0%) and NADP+ (1.0%) supplementation. This 
indicates that either NADP+ or NADPH was necessary for the recombinant human 11β-HSD1 
to carry out the interconversion of both 5α-reduced 7β-hydroxysteroids to 7α-hydroxylated 
epimers. Absence of label in 7-oxo-EpiA and 7-oxo-Adiol suggests that the enzyme does not 
use this intermediary oxidation step. 
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Steroid structure examination and docking within 11β-HSD1 active site 
Data computed within Kohn-Sham methodology (supplementary mol.2 data) helped 
modelling cortisone, cortisol and the six 7-hydroxysteroids and three 7-oxosteroids. 
Consideration of steroids bearing oxygen at the C7 positions and comparison relative to 
cortisol and cortisone lead to the following: the steroid may be positioned as cortisol or either 
flipped or turned (Fig. 2). The 7-oxo groups of all flipped or turned 7-oxosteroids could match 
correctly with the 11-oxo group of cortisone. In 7α-hydroxysteroids, the axial 7α- position 
could possibly match with the axial 11β-hydroxyl of cortisol only after a flip of the molecule. 
This was not the case with the equatorial 7β- position which stood opposite to the axial 11β-
hydroxyl when either flipped or flipped and turned. The turned molecule would be the only 
structure bringing the 7β-hydroxyl into the vicinity of the 11β-hydroxyl. It was also noticed 
that the formulae of ∆5 steroids did not superpose exactly with those of 5α-reduced steroids. 
These comparisons led us to examine the fitting of each steroid relative to Tyr183 and Ser170 in 
the active site of the cofactor-supplemented enzyme. Cortisone positioned in the NADPH-
fortified 11β-HSD1 active site proximal to the cofactor and to Tyr183 with minimum energy 
required (Table 2). No other cortisone position would dock properly within the site. This 
positioning results in cortisol production from cortisone reduction (Fig. 3). Once either turned 
or flipped, all 7-oxo-steroids were positioned in the site with the 7-oxo proximal to NADPH 
and to Tyr183. Nevertheless, the distance between 7-oxo and Tyr183 was larger in 7-oxo-EpiA 
and 7-oxo-Adiol than in cortisone and 7-oxo-DHEA (Table 2). This structure-related 
displacement brought the Ser170 closer to the 7-oxo group. Thus NADPH-dependent reduction 
occurred on either turned or flipped 7-oxo-steroids, and led to the production of 7β- and 7α-
reduced derivatives, respectively (Fig. 4). This positioning structural approach permits 
assessment of the events taking place in the active site. It indicates that production of 7α- and 
7β-reduced forms may result from two different docking positions of the 7-oxo-steroid 
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substrates in the active site. In contrast, with 5α-reduced 7α-hydroxysteroids, the turned 
structures met with minimum energy requirements and the 7α-hydroxyl was positioned closer 
to Ser170 than Tyr183 (Table 2). With 5α-reduced 7β-hydroxysteroids, the flipped formulae 
met with minimum energy requirements and the 7β-hydroxyl positioned was in close vicinity 
to Ser170 while Tyr183 became more distal (Table 2). Differences in positioning of either 7α-
hydroxy-EpiA and 7α-hydroxy-Adiol or 7β-hydroxy-Adiol and 7β-hydroxy-Adiol led us to 
question the absence of 7-oxo intermediate production and the interconversion process taking 
place in the presence of either NADPH or NADP+. The possibility of an epimerisation process 
taking place led to two hypotheses: i) once docked and oxidized, the turned 7α-hydroxy-EpiA 
carbanion could react with H2O and form an unstable ketone-hydrate leading to 7-oxo-EpiA 
immediately reduced to 7β-hydroxy-EpiA; ii) The turned 7α-hydroxy-EpiA carbanion could 
react with the proximal Ser170, to form a stable hemi-ketal reduced then by NADPH in 7β-
hydroxy-EpiA (Fig. 5). These mechanisms could apply to 7β-hydroxy-EpiA substrate after 
docking in the flipped position, and to 7α- and 7β-hydroxy-Adiol. Test of the first hypothesis 
required the use of H218O.  
 
Incubation of 7-oxygenated steroids in H218O-reconstituted medium 
We lyophilized 1 mg portions of the recombinant 11β-HSD1 in the presence of either NADP+ 
or NADPH, and tested their activity before carrying out incubations in the presence of H218O. 
As expected, no 18O enrichment was detected in 7α-hydroxy-DHEA or 7β-hydroxy-DHEA 
after incubation of 7-oxo-DHEA in the presence of NADPH. Both 7α-hydroxy-DHEA and 
7β-hydroxy-DHEA were oxidized into 7-oxo-DHEA in NADP+-fortified incubations without 
18O incorporation. As expected from the mechanism proposed above, the reduction of 7-oxo-
EpiA by NADPH produced both 7α-hydroxy-EpiA and 7β-hydroxy-EpiA containing no 18O. 
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In the presence of NADP+ as well as NADPH, 7α-hydroxy-EpiA and 7α-hydroxy-Adiol were 
converted to 7β-hydroxy-EpiA and 7β-hydroxy-Adiol containing no 18O (Table 3). The 18O-
content of 7α-hydroxy-EpiA obtained from 7β-hydroxy-EpiA could not be measured due to 
the very low transformation yields. Thus, the 11β-HSD1 converts 7-oxo-steroids into both 
7α- and 7β-epimers through a NADP(H)-dependent process which does not involve H2O 
from the medium.  
 
DISCUSSION 
We have already shown that the recombinant human 11β-HSD1 is an active NADP(H)-
dependent oxido-reductase interconverting cortisol and cortisone in addition to 7-oxo-DHEA 
and 7α-hydroxy-DHEA and 7β-hydroxy-DHEA10. This finding was extended to the native 
enzyme present in human skin tissue homogenates11. In the presence of NADPH, the 
recombinant human 11β-HSD1 reduced 7-oxo-DHEA into 7β-hydroxy-DHEA in preference 
to 7α-hydroxy-DHEA as indicated by a higher Vmax/KM ratio (Table 2)10. This preference for 
the 7β epimer was maintained in the NADP+-dependent oxidation of 7β-hydroxy-DHEA and 
7α-hydroxy-DHEA. Other assays with 7α- and 7β-hydroxylated derivatives of EpiA12 and 
Adiol13 gave results conflicting with those obtained with DHEA derivatives. Thus, the 
NADPH-dependent 7α-reduction of 7-oxo-epiA and 7-oxo-Adiol was preferred over the 7β-
reduction by the enzyme through Vmax/KM values as shown in Table 2.  In contrast to DHEA, 
the NADP+-dependent oxidation of 7α- and 7β-hydroxy-EpiA and 7α- and 7β-hydroxy-Adiol 
did not result in 7-oxo derivative productions. Instead, inter-conversion of the 7α- and 7β-
hydroxylated forms was observed, with a preference for the production of the 7β-
hydroxylated epimers12,13. From these findings on 5α-reduced steroids, the mechanism driven 
by the recombinant human 11β-HSD1 remained open. Did the interconversion proceed 
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through oxido-reductive steps or through a direct epimeric transformation? Oxido-reduction 
should process through ketone formation. Our previous kinetic studies indicated through 
apparent KMs and Vmax determinations that the conversion of 7α- into 7β- derivatives was 
preferred, as well as the reduction of 7-oxo into 7α- derivatives. On this basis, and because a 
very rapid oxido-reduction process could deplete the medium of a putative 7-oxo 
intermediate, we chose to use the 7β-hydroxysteroids as substrates for the recombinant human 
11β-HSD1 with and without NADP+ or NADPH supplementations. Search for a putative 7-
oxo intermediate was assessed with use of the [3H]-labelled 7β-hydroxysteroid together with 
the relevant non-radioactive 7-oxo-steroid for radioactivity trapping. In order to validate this 
model we used the known NADP+-dependent 11β-HSD1-catalyzed oxidation of 7β-hydroxy-
DHEA into 7-oxo-DHEA. Our evidence for [3H]-label in the 7-oxo-DHEA originating from 
[3H]-7β-hydroxy-DHEA indicated that the model was functional. No label occurred in the 
expected 7α-hydroxy-DHEA fraction with use of NADP+ supplementation. Use of NADPH 
supplementation did not yield any [3H]-7β-hydroxy-DHEA transformation product, thus 
indicating that the NADP+-dependent oxidation step was a prerequisite for a further 
transformation. The validated model used with either [3H]-7β-hydroxy-EpiA or [3H]-7β-
hydroxy-Adiol should yield [3H]-label accumulation in the 7-oxo-EpiA and 7-oxo-Adiol 
traps, respectively. No label was found in the two 7-oxo-steroid traps, but small amounts of 
the radioactivity occurred at the level of 7α-hydroxylated derivatives. These formations did 
not occur in the absence of cofactor and were more dependent on NADPH than NADP+. Two 
conclusions may be drawn from these findings. First, the recombinant human 11β-HSD1 does 
not carry out the NADP+-dependent oxidation of 7β-hydroxy-EpiA and 7β-hydroxy-Adiol to 
7-oxo-EpiA. Second, the enzyme carries out epimerisation of the 5α-reduced 7β-
hydroxysteroids independently of the cofactor oxidation state. Nevertheless, presence of the 
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cofactor was necessary for such epimerisation. It should be noted that the NADPH dependent 
reduction of 7-oxo-EpiA and 7-oxo-Adiol was described with a preferred production of the 
7α-hydroxylated derivatives12,13. It should also be noted that these findings obtained with the 
recombinant human 11β-HSD1 correlated well with other works using the native enzyme in 
human liver and intestinal preparations8,9. Interpretation of the present findings deserved 
assessment through close examination and comparison of the steroid structures relative to the 
enzyme activity. Cortisone and all 7-oxo steroids are substrates for the NADPH-dependent 
reduction by the recombinant 11β-HSD1. One may expect for the 11-oxo and 7-oxo groups an 
equivalent positioning proximal to NADPH within the enzyme active site. Indeed, either a flip 
or a turn of the 7-oxo-steroid structure does align the 7 and 11 sp2 carbons of 7-oxo steroids 
and cortisone, respectively, as previously suggested14,13 and as shown in Fig. 2. These model 
structures were computed within Kohn-Sham methodology (see supplementary mol.2 data) 
and their fitting into the 11β-HSD1 active site could be assessed. Thus, flipped formulae of 7-
oxo and 7β-hydroxysteroids were docked in the site, while turned formulae of 7-oxo-steroids 
and 7α-hydroxysteroids docked as well in the site (Fig. 3, Fig. 4). When applied to 7-oxo-
steroids, these two docking forms leads to the mechanism depicted in Fig. 4 where 7-
oxosteroids are reduced in the α or β position when docked in a turned or flipped position, 
respectively. This proposal is made attractive by the explanation it may provide for the 
stereospecific reduction of 7-oxo-cholesterol to 7β-hydroxy-cholesterol, exclusively15,16,17. 
Our model make it apparent that due to its large side chain, 7-oxo-cholesterol docking into the 
11β-HSD1 active site may occur in the flipped position only, thereby leading to its reduction 
to 7β-hydroxy-cholesterol only.  
Tyr183 is located proximal to the bound cofactor within the human 11β-HSD1 active site and 
is responsible for the reducing activity18,19. This is shown in Fig. 4 and Table 2 with 
measured distance between the C7-borne oxygen and Tyr183, Ser170 and the hydrogen donor C4 
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of nicotinamide. The affinity of each 7-oxo-steroid for the active site (KM) is not modified 
with the flipped or turned positions. Activity of the enzyme (Vmax/KM) may be related to short 
distances between the nicotinamide C4-borne active hydrogen and the 7-oxo group, more so 
than distances from Tyr183 and Ser170. Nevertheless, once produced, both 7α- and 7β-
hydroxylated 5α-reduced steroids fit closer to Ser170 than to Tyr183.  In 5α-reduced derivatives 
(7α-hydroxy-EpiA, 7α-hydroxy-Adiol, 7β-hydroxy-EpiA, 7β-hydroxy-Adiol), absence of the 
5-ene double bond and replacement of the sp2 C5 and C6 by sp3 structures induce major 
changes in the steroid structural configuration and alignment with cortisol. Our results 
indicate that occupation of the cofactor site was necessary for enzymatic action, but that 
neither NADP+ nor NADPH modified the formation of 7α-and 7β-epimeric derivatives, and 
that no 7-oxo intermediate occurred in the trap. These observations led to question the oxido-
reductive process. Since docking of 5α-reduced 7-hydroxysteroids brought the 7-hydroxyl in 
the close proximity of Ser170, we hypothesize that cofactor-driven epimerisation could 
proceed either with use of a molecule of water or through a more stable hemi-ketal with Ser170 
as depicted in Fig. 5. Validation of the first hypothesis required experimental test where 
H218O replaced H2O contained in the enzyme site. Natural water was removed from cofactor 
loaded 11β-HSD1 by lyophilisation. Incubations with steroid substrates were carried out then 
in a medium reconstituted with H218O and no 18O enrichment occurred in the “epimerized” 
products. These results imply that the second hypothesis involving Ser170 as responsible for 
the epimerisation process is held to be valid. This proposal relates well with the 7-oxygen 
distances from Ser170 and cofactor (Table 2) as well as with the measured KM and Vmax/KM 
ratios (Table 3). 
 
 
METHODS 
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Steroids. DHEA, EpiA and Adiol were obtained from Sigma-Aldrich. 7-Oxo-DHEA was 
from Steraloids. The 7-oxo-Adiol was donated by Sir E.R.H. Jones (Oxford, UK). Custom 
chemical synthesis by Roowin S.A. (Romainville, France) provided mg quantities of 
chemically pure 7α-hydroxy-DHEA, 7α-hydroxy-EpiA, 7β-hydroxy-DHEA, 7β-hydroxy-
EpiA and 7-oxo-DHEA-17-ethylene-ketal. The latter steroid was reduced with hydrogen gas 
in the presence of Pd into 3β-hydroxy-5α-androstane-17-ethylene-ketal. After HCl treatment, 
the 3β-hydroxy-5α-androstane-7,17-dione (7-oxo-EpiA) was obtained. Both 7α-hydroxy-
Adiol and 7β-hydroxy-Adiol were obtained after NaBH4 (Sigma-Aldrich) reduction of 7α-
hydroxy-EpiA and 7β-hydroxy-EpiA, respectively. The produced steroids were all purified by 
preparative HPLC and their identity and purity were assessed after GC/MS with evidence for 
a single peak containing the relevant molecular ion. [1,2,6,7-3H] DHEA ( 74 Ci/mmol) and 
[1,2,4,5,6,7-3H] dihydrotestosterone (110 Ci/mmol) were purchased from the New England 
Nuclear Corporation and were used for the production of [1,2,6-3H] 7β-hydroxy-DHEA (61.4 
Ci/mmol) and [1,2,4,5,6-3H] 7β-hydroxy-EpiA (91.3 Ci/mmol) as previously described20. 
[1,2,4,5,6-3H] 7β-Hydroxy-Adiol was obtained then after reduction of [1,2,4,5,6-3H] 7β-
hydroxy-EpiA by AlLiH4. H218O (97% 18O) was from Euriso-top (Saint Aubin, France). All 
solvents were of the reagent grade and obtained from Merck. 
 
Steroid structure studies. The density functional theory within the Khon-Sham 
methodology21 was used to model cortisol, cortisone and the 7-oxygenated steroids. The 
generalized gradient approximation was employed within Perdew-Burke-Ernzerhof exchange-
correlation functional formulation22. Calculations were performed with use of the ADF06 
program package23,24. The basis set was of triple-zeta quality + polarization with small frozen 
cores. Finally, the integration grid parameter, setting the numerical integration accuracy, was 
fixed to 5 (supplementary mol.2 data). 
 
The recombinant human 11β-HSD1. The recombinant human 11β-HSD1 was obtained in 
microsomes of the Sacharomyces cervisiae strain W303-1B (Mata; leu2-3,112, his3-11,15; 
ade2-1; trp1-1; ura3-1; canR; cyr+) transformed with the V60-HSD1 construct as previously 
described10.  
 
Bioinformatic analysis. The crystal structure of the human 11β-HSD1 with NADP was 
retrieved from the Protein Data Bank25 (PDB code 1ILT). All heteroatoms were removed 
from the file and hydrogen atoms were added using the QuacPac program from Openeye 
Scientific Software. The docking experiments of the different steroids were performed using 
the flexible docking program Surflex26. The binding site for docking experiments was defined 
around the co-crystallized Adamantane Sulfone inhibitor. The 10 top scoring poses after 
docking were visually inspected in order to propose a binding mode for each compound. 
Selected images were generated by PyMol software. 
 
Incubation protocols. Two different protocols were used, one for incubation with 
radiolabeled steroids, the second for incubation in 97% H218O. i) Each 7β-hydroxysteroid (0.5 
µmol) spiked with 20,000 dpm of the relevant [3H]-steroid was mixed with 0.5 µmol of the 
relevant 7-oxo-steroid and dried under vacuum at the bottom of 10 mL glass tubes prior to 
addition of 66.7 mM K2HPO4/KH2PO4 buffer (pH 7.4) containing 1 mM EDTA. The mixture 
was pre-incubated at 28°C for 5 min. The cofactor (either 1 µM NADP+ or NADPH in 500 
µL buffer) was added to the steroid substrates. Incubations commenced at the addition of a 
suspension of yeast microsomes containing the 11β-HSD1 (63.8 µL, 1 mg protein) and 
addition of buffer to the 1 mL mark. The process continued in a shaking water bath at 28°C 
for 30 min. ii) Tubes containing aliquot portions of the buffered enzyme suspension (1 mL, 1 
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mg protein) were added with either NADP+ or NADPH and lyophilized. In order to avoid the 
putative reinsertion of environmental water, a H218O spray was produced at the moment of 
vacuum breaking. The medium was reconstituted with 1 mL H218O and the mixture was pre-
incubated at 28°C for 5 min. Incubation commenced at the addition of the steroid substrate in 
10µL ethanol. The process continued in a shaking water bath at 28°C for 30 min. All 
incubations ceased at the addition of 0.5 mL acetone followed by 2 mL ethyl acetate. 
Extraction of the steroids was carried out with 2 mL ethyl acetate and was repeated three 
times.  
 
Steroid separation and analysis. The radio-steroids extracted were analyzed by TLC. The 
separation of 7α-hydroxy-DHEA (Rf 0.25) from 7β-hydroxy-DHEA (Rf 0.38) and 7-oxo-
DHEA (Rf 0.55) on silica 60-coated glass plates (Merck, Darmstadt, Germany) required one 
development in ethyl acetate. Aluminium oxide-coated polyester plates from Machery-Nagel 
were developed twice in ethyl acetate for the separation of 7α-hydroxy-EpiA (Rf 0.47) from 
7β-hydroxy-EpiA (Rf 0.55) and 7-oxo-EpiA (Rf 0.79). The same system and plates were used 
for the separation of 7α-hydroxy-Adiol (Rf 0.35) from 7β-hydroxy-Adiol (Rf 0.47) and 7-oxo-
Adiol (Rf 0.55). The steroid containing zones were scrapped off the plate and counted. The 
counting of each sample was carried out for 30 min in order to accumulate sufficient counts 
for precise dpm measurements. Steroids recovered after incubations in the presence of H218O 
were transformed into TMS derivatives and analyzed by GC/MS as previously reported8.  
 
Note: Supplementary data (supplementary mol.2 data) are freely available on 
http://bioinfo.cnam.fr/bioinfo/structuresteroidsinmol2/ 
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Table 1: Incubation of 0.5 µM 7β-hydroxy-DHEA (a) 7β-hydroxy-EpiA (b) and 7β-hydroxy-
Adiol (c) spiked with [1,2,6-3H]-7β-hydroxy-DHEA (20,000 dpm),  [1,2,4,5,6-3H]-7β-
hydroxy-EPIA (20,000 dpm) and [1,2,4,5,6-3H]-7β-hydroxy-Adiol (20,000 dpm) in the 
presence of 0.5 µM 7-oxo-DHEA,  7-oxo-EPIA and  7-oxo-Adiol trap, respectively. Steroids 
from (a) were extracted after incubation and separated by TLC on silica before recovery (47-
70 %) and counting. Steroids from (b) and (c) were extracted after incubation and separated 
by TLC on aluminium oxide before recovery (46-55 %) and counting. The background (24 
dpm) was subtracted from each count. Data (dpm ± SEM) are means resulting from 3 separate 
experiments.  
 
 
(a) 
Cofactor 
Incubation 
conditions 
[3H]-7α-hydroxy-
DHEA fraction 
[3H]-7β-hydroxy-
DHEA substrate 
[3H]-7-oxo-
DHEA fraction 
11β-HSD1 0 9,561 ± 1,587 0 
Boiled 11β-HSD1 0 9,458 ± 1,095 0 
 
NADPH 
(1 µM) No 11β-HSD1 0 11,446 ± 411 0 
11β-HSD1 0 9,050 ± 539 5,760 ± 527 
Boiled 11β-HSD1 0 11,085 ± 714 0 
 
NADP+ 
(1 µM) No 11β-HSD1 0 10,633 ± 455 0 
11β-HSD1 0 10,789 ± 269 0 
Boiled 11β-HSD1 0 12,533 ± 125 0 
 
None 
No 11β-HSD1 0 10,790 ± 269 0 
 (b) 
Cofactor 
 [3H]-7α-hydroxy-
EpiA fraction 
[3H]-7β-hydroxy-
EpiA substrate  
[3H]-7-oxo-
DHEA fraction 
 
NADPH 
(1 µM) 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
138 ± 8 
0 
0 
10,119 ± 435 
9,865 ± 172 
9,807 ± 246 
0 
0 
0 
 
NADP+ 
(1 µM) 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
100 ± 14 
0 
0 
10,048 ± 352 
10,147 ± 192 
10,011 ± 285 
0 
0 
0 
 
None 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
0 
0 
0 
10,803 ± 97 
9,705 ± 212 
9,364 ± 198 
0 
0 
0 
(c) 
Cofactor 
 [3H]-7α-hydroxy-
Adiol fraction 
[3H]-7β-hydroxy-
Adiol substrate  
[3H]-7-oxo-
Adiol fraction 
 
NADPH 
(1 µM) 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
746 ± 127 
0 
0 
10,562 ± 163 
9,699 ± 227 
9,664 ± 119 
0 
0 
0 
 
NADP+ 
(1 µM) 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
164 ± 6 
0 
0 
9,706 ± 138 
9,810 ± 279 
9,650 ± 140 
0 
0 
0 
 
None 
11β-HSD1 
Boiled 11β-HSD1 
No 11β-HSD1 
0 
0 
0 
9,706 ± 366 
9,987 ± 271 
9,864 ± 234 
0 
0 
0 
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Table 2: 11β-HSD1-mediated reduction of cortisone and 7-oxo-steroids. Kinetic parameters 
were previously reported 10,12,13. Distances between the oxygen borne at the steroid 7-position 
and Tyr183, Ser170 hydroxyl groups and active hydrogen-bearing C4 of nicotinamide (NA) in 
NADPH are given. The distances in brackets are those measured in each product deriving 
from the reduction process. Each steroid model was positioned and docked at minimum 
energy settings into the computerized crystal structure of the human 11β-HSD1. Distances 
were obtained through use of PyMol software. 
 
 
Substrate 
(position) 
Product 
(position) 
KM 
(µM) 
Vmax/KM Tyr183  
(Ǻ) 
Ser170   
(Ǻ) 
NA  
(Ǻ) 
Cortisone Cortisol 2.8 0.4 
2.85 
[1.81] 
2.10 
[2.68] 
1.90 
[2.30] 
7-Oxo-DHEA 
(turned) 
7α-Hydroxy-DHEA 
(turned) 1.15 0.5 
5.00 
[3.16] 
5.37 
[2.25] 
2.45 
[2.34] 
7-Oxo-DHEA 
(flipped) 
7β-Hydroxy-DHEA 
(flipped) 1.13 7.4 
2.31 
[3.81] 
1.91 
[5.81] 
2.29 
[4.97] 
7-Oxo-EpiA 
(turned) 
7α-Hydroxy-EpiA 
(turned) 0.57 23.7 
4.40 
[3.91] 
1.99 
[1.77] 
1.91 
[1.93] 
7-Oxo-EpiA 
(flipped) 
7β-Hydroxy-EpiA 
(flipped) 0.52 5.8 
2.34 
[2.06] 
3.42 
[1.98] 
2.29 
[2.57] 
7-Oxo-Adiol 
(turned) 
7α-Hydroxy-Adiol 
(turned) 5.1 3.43 
5.60 
[2.94] 
4.93 
[2.04] 
1.84 
[1.96] 
7-Oxo-Adiol 
(flipped) 
7β-Hydroxy-Adiol 
(flipped) 6.8 0.22 
3.11 
[1.81] 
3.20 
[1.96] 
2.11 
[2.42] 
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Table 3: 11β-HSD1-mediated 7-hydroxysteroid epimerisation: 18O incorporation from H218O. 
Lyophilized 11β-HSD1 (1 mg) containing either NADPH or NADP+ was reconstituted in 
97% H218O prior to incubation with selected 7-oxygenated steroids. Substrates and 
metabolites were recovered, transformed into TMS derivatives and separated and analyzed by 
gas chromatography-mass spectrometry (GLC/MS). 18O content of metabolites (M+2) was 
measured in M+ and M+-15 ions after comparison with M+2 levels in the same ions from 
authentic standards. * Conversion rate too low for measurement. 
 
 
Conversion Yield (%) of 
metabolite 
18O content in 
metabolite  
KM 
(µM) 
Vmax/KM 
7-oxo-DHEA to 7α-hydroxy-DHEA 49 0 1.15 0.5 
7-oxo-DHEA to 7β-hydroxy-DHEA 30 0 1.13 7.4 
7α-hydroxy-DHEA to 7-oxo-DHEA 66 0 70.0 0.2 
7β-hydroxy-DHEA to 7-oxo-DHEA 90 0 9.5 1.9 
7-oxo-EpiA to 7α-hydroxy-EpiA 70 0 0.57 23.7 
7-oxo-EpiA to 7β-hydroxy-EpiA 30 0 0.52 5.8 
7α-hydroxy-EpiA to 7β-hydroxy-EpiA 90 0 8.1 0.1 
7β-hydroxy-EpiA to 7α-hydroxy-EpiA 0.1 0 * * 
7-oxo-Adiol to 7α-hydroxy-Adiol 41 0 5.1 3.43 
7-oxo-Adiol to 7β-hydroxy-Adiol 43 0 6.8 0.22 
7α-hydroxy-Adiol to 7β-hydroxy-Adiol 55 0 1.2 2 
7β-hydroxy-Adiol to 7α-hydroxy-Adiol 40 0 21.0 0.5 
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Figure legends 
Figure 1   11β-HSD1 mediated oxido-reduction and interconversion of the 7α- and 7β-
hydroxylated derivatives of a: dehydroepiandrosterone (DHEA), b: epiandrosterone (EpiA) 
and c: 5α-androstane-3β,17β-diol (Adiol). Apparent Vmax/KM ratio values 10,12,13 are indicated 
for each NADP(H)-dependent reaction step. Absence of product formation is depicted by 
question marks and concerns the putative 11β-HSD1 mediated direct interconversion process.  
 
Figure 2 Possible positioning relative to cortisone or cortisol for 7-oxygenated steroids in the 
11β-HSD1 active site. Structure models were generated from computation within Kohn-Sham 
methodology (supplementary mol.2 data). The twelve 7-oxygenated DHEA derivative 
positions were selected for this tabular figure. Steroid backbone, oxygen and hydrogen are 
depicted in blue, red and white, respectively. 
  
Figure 3 Docking of steroid structures within the 11β-HSD1 active site.  The crystal structure 
of the human 11β-HSD1 retrieved from the Protein Data Bank (PDB code 1ILT) was used 
with QuacPac program from Openeye Scientific Software. Docking of the different steroids 
was performed using the flexible docking program Surflex. Cortisol (with NADP+) and 
cortisone (with NADPH) native substrates were positioned in the site relative to Tyr183, Ser170 
(orange) and nicotinamide from NADP(H) (black) at minimum energy settings. Steroid 
backbone, oxygen and hydrogen are depicted in blue, red and white, respectively. 7oxo- and 
7-hydroxysteroids fitted proximal to the cofactor and Tyr183 and Ser170 after either a turn or a 
flip of their structures relative to cortisone and cortisol, respectively. In this tabular figure the 
flip for 7-oxo-steroids and 7β-hydroxysteroids and the turn of 7α-hydroxysteroids 
exemplified in Fig. 2 were selected, respectively.  
  
Figure 4 Proposed mechanism generating both 7α- and 7β-hydroxysteroids after 11β-HSD1-
catalyzed NADPH-dependent reduction of 7-oxo-steroid precursors. The crystal structure of 
the human 11β-HSD1 retrieved from the Protein Data Bank (PDB code 1ILT) was used with 
QuacPac program from Openeye Scientific Software. Docking of the different steroids was 
performed using the flexible docking program Surflex. The steroid substrates (blue) and 
products were docked in the site relative to Tyr183, Ser170 (orange) and nicotinamide from 
NADP(H) (black) at minimum energy settings for each flipped or turned structure. Enzymatic 
reduction of turned structures results in 7α-hydroxylated product while flipped structures 
result in 7β-hydroxylated products. 
 
Figure 5 Hypotheses for 11β-HSD1-catalyzed epimerisation of 5α-reduced 7-
hydroxysteroids. The steroid depicted is 7α-hydroxy-EpiA docked in the enzyme site with the 
7α-hydroxyl proximal to Ser170 and distal to Tyr183. The first hypothesis involves one 
molecule of H2O which provides the –OH necessary for epimerisation to proceed through 
ketone-hydrate formation and a 7-ketone intermediate. Absence of 18O enrichment after use of 
H218O eliminated such hypothesis. The second hypothesis implies reaction of Ser170 for hemi-
ketal production prior to reduction. This model applies as well to 7α-hydroxy-Adiol and 7β-
hydroxy-Adiol. Once produced, the 7β-hydroxy of 7β-hydroxy-EpiA becomes distal to Ser170 
and this may justify the difficulty for the back reaction to proceed.   
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Fig. 1  
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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